Rickard Kathleen A.

CMO Kathleen A. Rickard sold 58,336 shares of VRNA at $13.14 on 2025-08-01; stock has surged 52.4% in 90 days post-trade.

Rickard Kathleen A., Chief Medical Officer, disposed of 58,336 shares (2.2% of pre-transaction holdings) at $13.14 on 2025-08-01, raising $766,750.88. The timing of this sale merits attention: VRNA has gained 52.4% over the 90 days following the transaction, and 15.2% in the 30 days immediately after. Across her prior three sales at VRNA, this insider's track record shows average 90-day returns of +1,095.6%, with 0 of 3 prior sells being well-timed by the metric that a sell is well-timed only if the stock falls afterward. The company remains unprofitable (net income $-16,319,000.00 for the latest quarter) despite generating $76,256,000.00 in quarterly revenue. The large post-transaction price appreciation relative to the $13.14 sale price suggests the insider may have exited ahead of a sustained rally, though her historical timing pattern at this ticker shows no evidence of predictive accuracy in identifying declines after sales.

Verona Pharma CMO Rickard sold 114,984 shares at $8.82 on 2025-05-06; stock now $66.26. Holdings remain substantial at 2,546,472 shares.

Rickard Kathleen A., Chief Medical Officer, sold 114,984 shares at $8.82 on 2025-05-06 for a total value of $1,014,342.85, reducing her holdings by 4.3% to 2,546,472 shares. The transaction price of $8.82 stands in stark contrast to the current price of $66.26, representing a 651% increase from the sale date—suggesting this sale occurred during a period of substantial stock undervaluation. Her same-ticker history at VRNA shows two prior sells on 2025-03-12 and 2024-11-25, both posting strong 30-day returns (+591.0% and +818.9% respectively), though the 2024-11-25 sell's 90-day outcome of +1286.5% indicates the stock rose sharply after the sale. The company remains unprofitable (net income of $-16,319,000 in the latest quarter), which may provide context for insider sales during this valuation period. Despite the dramatic subsequent price appreciation, the sale does not align with a pattern of well-timed exits, as the 90-day timing rate across her same-ticker history stands at 0% (0 of 1 prior sells were well-timed at the 90-day mark).

CMO Kathleen A. Rickard sold 79,264 shares of VRNA at $8.35 on 2025-03-12 ($661,941.59); retains 2,608,976 shares.

Kathleen A. Rickard, Chief Medical Officer, executed an open-market sale of 79,264 shares at $8.35, reducing her position by 2.9% to 2,608,976 shares. The current price of $65.36 represents a substantial move from the $8.35 transaction price, but this transaction occurred well before the recent 57.8% 90-day gain, indicating the timing relative to that recovery was not predictive. Her prior sales at this ticker yielded a 90-day return of +1286.5%, which represents poor timing in the historical sense—the stock rose significantly after she sold. The company remains unprofitable (net income $-43,000,000 in its most recent full fiscal year) with minimal revenue of $5,600,000, creating material operational concerns that may have motivated liquidity decisions. The significant gap between transaction price and current price reflects substantial equity appreciation since the sale, but the insider's prior sales at VRNA have not demonstrated forward-looking accuracy in avoiding gains.

Verona CMO Rickard sells 240,000 shares at $4.90; stock has soared +17.7% (30-day), +48.0% (90-day) from trade date.

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma, executed a 240,000-share sale at $4.90 on 2024-11-25, reducing her holdings from 2.91M to 2.67M shares. The sale occurred when the stock was trading sharply below current levels ($39.84), having since appreciated approximately +17.7% over the 30 days and +48.0% over the 90 days following the transaction. Meanwhile, the company remains deeply unprofitable with annual revenue growth of -100.0% and a full-year net income of $-43.0M, creating an apparent disconnect between fundamental weakness and post-sale price momentum. This transaction represents a material liquidation by a high-ranking officer during a period of significant stock appreciation and ongoing operational losses.